Another Buy RecommendationMackie Research Capital has reiterated its "buy" recommendation for Nobilis Health Corp. (NHC-T; HLTH-N) with a 12-month price target of $12.50. Mackie cites the appointment of Kenny Klein to the role of chief financial officer, the appointment of former CFO, Andy Chen, to the role of executive vice-presdient of Finance, and Dr. Neil Badlani as vice-president of Medical Affairs. We view the appointments positively, particularly the addition of Mr. Kleins post transaction integration experience, given NHCs acquisition strategy. We continue to view NHC as an attractively priced play on the U.S. health care market. An aging population and the prevalence of obesity are driving demand for a number of high acuity surgical procedures. Meanwhile, increasing cost sensitivity amongst healthcare payers and providers make cost-effective alternatives to traditional hospitals more attractive.